Due to its CD80-suppressing ability, triptolide plays an important role in rheumatoid arthritis treatment [78], and CD80 expression is linked to the frequent relapse of the group of minimal change diseases, a form of chronic kidney disease [79]. This evidence concerns the gene CD80 and rheumatoid arthritis.